Clinical Trials

Carcinoma, Hepatocellular

NCT06235918 2024-02-01

Neoadjuvant Tislelizumab Plus Chemotherapy for Resectable Locally-advanced Head and Neck Squamous Cell Carcinoma

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT06233981 2024-01-31

Phase II Study of Moderate-dose Hypofractionated RT Combined With Tislelizumab for HCC With Diffuse Tumor Thrombosis

Carcinoma, Hepatocellular

NCT04914390 2024-01-22

NeoATCT

32 enrolled

Triple Negative Breast Neoplasms

NCT05435313 2024-01-17

Fruquintinib Combined With Tislelizumab and HAIC in Patients With Advanced Colorectal Liver Metastases Cancer Who Failed Standard Therapy

39 enrolled

Colorectal Neoplasms

NCT05611879 2023-12-29

Neoadjuvant of Tislelizumab Combined With Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLC

Carcinoma, Non-Small-Cell Lung

NCT05533892 2023-12-19

CCGLC-007

Phase 1 Unknown

Carcinoma, Hepatocellular

NCT05578287 2023-12-07

DETECT

29 enrolled

Colorectal Neoplasms

NCT06154967 2023-12-04

To Explore the Effect of Immune-induced Stereotactic Body Radiotherapy (SBRT) on Reversing Immunoresistance in Stage IIIc/IV Non-small Cell Lung Cancer (NSCLC)

Phase NA Unknown

20 enrolled

Non-Small Cell Lung Cancer Without Mutation in Epidermal Growth Factor Receptor (Disorder)

NCT05588219 2023-11-24

Tislelizumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer

Gynecologic

Uterine Cervical Neoplasms

NCT04734262 2023-11-18

SPARK

98 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06134193 2023-11-18

Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract Cancer

41 enrolled

Carcinoma, Gallbladder Neoplasms, Cholangiocarcinoma

NCT06059885 2023-09-29

Tislelizumab Plus TKI as Adjuvant Therapy Versus Active Surveillance in Patients With HCC

Liver Neoplasms

NCT05228496 2023-09-26

A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Sitravatinib as Maintenance Therapy for ES-SCLC

21 enrolled

Small Cell Lung Carcinoma

NCT05176964 2023-09-25

Chemotherapy and Tislelizumab With Split-course HFRT for Locally Advanced Rectal Cancer

Unknown

50 enrolled

Rectal Neoplasms

NCT06034964 2023-09-13

Tislelizumab Combined With Chemotherapy in First-line Treatment of AGC

Unknown

Stomach Neoplasms

NCT04902261 2023-09-01

Tislelizumab Combined With Nab-paclitaxel and Gemcitabine for Recurrent Pancreatic Cancer

140 enrolled

Pancreatic Neoplasms

NCT05982834 2023-08-09

Disitamab Vedotin, Fruquintinib and Tislelizumab in Second-line Treatment for HER2-positive MGC

43 enrolled

HER2-positive Gastric Cancer

NCT05798533 2023-07-10

Neo-T in Treating Patients With Advanced Solid Tumors(GI-NeoT-03)

Phase 1 Unknown

6 enrolled

DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma

NCT05603065 2023-06-29

TINES

Phase 4 Unknown

32 enrolled

Esophageal Squamous Cell Carcinoma

NCT05823987 2023-06-27

OPTIONS-05

Advanced Biliary Tract Cancer

NCT05893056 2023-06-27

CASTLE-09

Gastric Cancer Metastatic to Liver

NCT05900921 2023-06-13

Trilaciclib Prior to Chemotherapy Plus Tislelizumab as 1L Treatment for Advanced Squamous Non-Small-Cell Lung Cancer

132 enrolled

Advanced Squamous Non-Small-Cell Lung Cancer

NCT05681390 2023-06-09

Tislelizumab With Anlotinib and Chemotherapy for Second-line Treatment of Pancreatic Cancer

Pancreatic Neoplasms

NCT05527808 2023-06-08

A Single-arm Exploratory Study of Neoadjuvant Therapy

Phase NA Unknown

28 enrolled

Adenocarcinoma of Lung

NCT05861635 2023-05-17

The Study of Vidicizumab Combined With Tirelizumab in the Treatment of Breast Cancer With Low HER2 Expression

Phase 4 Unknown

42 enrolled

Breast Neoplasms

NCT05420584 2023-05-11

NECI

83 enrolled

Rectal Neoplasms

NCT05833984 2023-04-27

Safety and Efficacy of IMM01 Plus Tislelizumab in Patients With Advanced Solid Tumors and Lymphomas

LymphoidOther solid neoplasm

309 enrolled

Solid Tumor

NCT04652440 2023-04-19

Ablation Combined With PD-1 in HCC: Phase II Study

Carcinoma, Hepatocellular

NCT05400902 2023-04-13

HAIC Combined With Sintilimab and Bevacizumab for Unresectable Intrahepatic Cholangiocarcinoma

17 enrolled

Cholangiocarcinoma

NCT05811793 2023-04-13

Efficacy and Safety of SCAI of Bevacizumab Combined With IC of Tislelizumab in the Treatment of Recurrent Glioblastoma.

Phase NA Unknown

36 enrolled

CNS

Glioblastoma

NCT05746728 2023-04-06

Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast Cancer

45 enrolled

Triple Negative Breast Neoplasms

NCT04663035 2023-03-22

Ablation Plus Tislelizumab Versus Ablation Alone for Intrahepatic Recurrent Early Stage HCC

120 enrolled

Carcinoma, Hepatocellular

NCT04985721 2023-03-15

IMPARP-HRD

Tumor-Agnostic

Neoplasms

NCT05675462 2023-03-06

Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib as Second-line or Later Therapy in Patients With Advanced Hepatocellular Carcinoma

Phase 1 Unknown

Carcinoma, Hepatocellular

NCT05325528 2023-02-01

Study of Tislelizumab in Combination With SOX for the Treatment of Gastric Cancer With Liver Metastases

Phase 2/3 Unknown

40 enrolled

Stomach Neoplasms

NCT05445648 2022-12-28

CBPTMI

65 enrolled

Urinary Bladder Neoplasms

NCT05659186 2022-12-21

PD-1 Inhibitor and Anlotinib Combined With Multimodal Radiotherapy in Recurrent or Metastatic Anaplastic Thyroid Cancer

20 enrolled

Head & Neck

Thyroid Neoplasms

NCT05634564 2022-12-05

Concurrent Chemoradiotherapy Combined With Immunotherapy in Patients With Potentially Resectable Pancreatic Cancer

62 enrolled

Pancreatic Neoplasms

NCT04730219 2022-11-30

Perioperative Tislelizumab Combined With Nab-Paclitaxel for Muscle-invasive Urothelial Bladder Carcinoma

48 enrolled

Carcinoma, Transitional Cell

NCT05596890 2022-11-28

PICCRT

50 enrolled

Esophageal Squamous Cell Carcinoma, Deglutition Disorders

NCT05493683 2022-10-21

Disitamab Vedotin Combined With Tislelizumab in Advanced HER2 Positive Colorectal Cancer

29 enrolled

Colorectal Neoplasms

NCT05580354 2022-10-14

Safety and Efficacy of BCG Combined With Tislelizumab for BCG-untreated Patients With High-risk Non-muscle Invasive Bladder Cancer

Phase 4 Unknown

42 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT05036798 2022-09-07

Tislelizumab+Lenvatinib+Gemox Regiment for Potentially Resectable Locally Advanced Malignant Tumors of Biliary System.

Potentially Resectable Locally Advanced Malignant Tumors of Biliary System

NCT04782804 2022-08-18

Adjuvant PD-1 Antibody in Combination With Capecitabine for Patients With ICC at High-Risk of Postoperative Recurrence

Cholangiocarcinoma

NCT05401279 2022-08-18

Bladder Sparing Treatment of Tislelizumab, Gemcitabine and Cisplatin for Patients With PD-L1 Positive Muscle Invasive Bladder Cancer

20 enrolled

Urothelial Carcinoma Bladder

NCT04924179 2022-08-17

Tislelizumab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With Advanced CRC

Patients With Advanced Metastatic Colorectal Cancer

NCT05290116 2022-08-05

HAIC Combined With Tislelizumab and Apatinib for Unresectable Intrahepatic Cholangiocarcinoma

17 enrolled

Cholangiocarcinoma

NCT05469061 2022-07-21

Tislelizumab in Combination With Chemotherapy for Conversion Therapy of Locally Nonresectable ESCC

17 enrolled